Key facts
- This page summarizes David E. Wheadon's Form 4 filing for Karuna Therapeutics, Inc..
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 22 Jun 2023, 16:18.
David E. Wheadon - 20 Jun 2023 Form 4 Insider Report for Karuna Therapeutics, Inc.
- Reporting relationship
- Director
- Issuer ticker
- N/A
- Reported as of
- 20 Jun 2023
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 22 Jun 2023, 16:18:42 UTC
- Prior SEC filing
- 31 May 2023
- Next SEC filing
- 01 Aug 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Troy Ignelzi, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
David E. Wheadon filed Form 4 for Karuna Therapeutics, Inc. on 22 Jun 2023.
Change
- Previous filing in this sequence was filed on 31 May 2023.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
KRTX
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +990
- Change %
- Price
- $0.000000
- Shares after
- 990
- Date
- 20 Jun 2023
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
KRTX
transaction
Derivative
Option (right to buy)
Award
- Transaction value
- $0
- Shares
- +1,904
- Change %
- Price
- $0.000000
- Shares after
- 1,904
- Date
- 20 Jun 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 1,904
- Exercise price
- $237.70
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Comprised of restricted stock units ("RSUs"), each representing a contingent right to receive one share of the Issuer's common stock. The RSUs shall vest in full upon the earlier of (i) June 20, 2024, and (ii) the 2024 annual meeting of the Issuer's stockholders, subject to continued service through such dates.
Footnote F2
This option shall vest in full upon the earlier of (i) June 20, 2024, and (ii) the 2024 annual meeting of the Issuer's stockholders, subject to continued service through such dates.